Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by na...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantini, Fabrizio, Niccoli, Laura, Nannini, Carlotta, Matarrese, Daniela, Natale, Massimo Edoardo Di, Lotti, Pamela, Aquilini, Donatella, Landini, Giancarlo, Cimolato, Barbara, Pietro, Massimo Antonio Di, Trezzi, Michele, Stobbione, Paolo, Frausini, Gabriele, Navarra, Assunta, Nicastri, Emanuele, Sotgiu, Giovanni, Goletti, Delia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313480/
https://www.ncbi.nlm.nih.gov/pubmed/32592703
http://dx.doi.org/10.1016/j.jinf.2020.06.052
Descripción
Sumario:• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. • Baricitinib used for 2 weeks was not associated with serious adverse events.

Ejemplares similares